España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
BioAtla
BCAB
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.4740
0.01
2.35%
At close: -
$0.4868
0.01
2.70%
After Hours: 4:16 PM EDT
Get Report
Comment
BioAtla (BCAB) Forecast
News
Earnings
BioAtla (BCAB) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for BioAtla (NASDAQ:BCAB) Stock
BioAtla Stock (NASDAQ: BCAB)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, December 20, 2024
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
BioAlta shares are trading lower after the co...
Benzinga Newsdesk
BioAtla Announces $9.2M Registered Direct Off...
Benzinga Newsdesk
Monday, December 16, 2024
BioAtla Presented Data Characterizing Mutated...
Benzinga Newsdesk
BioAtla Presented Posted Titled 'Characteriza...
Benzinga Newsdesk
Thursday, November 14, 2024
BioAtla shares are trading lower. The stock m...
Benzinga Newsdesk
Scion Asset Management 13F Shows Exited Posit...
Benzinga Newsdesk
Wednesday, November 13, 2024
HC Wainwright & Co. Downgrades BioAtla to Neu...
Benzinga Newsdesk
Thursday, November 07, 2024
BioAtla Q3 2024 GAAP EPS $(0.22) Beats $(0.39...
Benzinga Newsdesk
Wednesday, October 09, 2024
'Big Short' Investor Michael Burry's China Bet Pays Off As Top Picks Surge Nearly 60% In 2 Months
Kaustubh Bagalkote
Wednesday, October 02, 2024
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights
Monday, September 23, 2024
Context Therapeutics Secures Global Rights to...
Benzinga Newsdesk
Monday, September 16, 2024
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
BioAtla Presented Phase 2 Ozuriftamab Vedotin...
Benzinga Newsdesk
Thursday, August 15, 2024
'Big Short' Fame Michael Burry Bets Big On China, Reveals Alibaba As Top Holding — JD.com And Baidu Also Feature On Scion's Portfolio
Kaustubh Bagalkote
Wednesday, August 14, 2024
Watching Shares Of BioAtla, Olaplex Holdings;...
Benzinga Newsdesk
Thursday, August 08, 2024
BioAtla Q2 2024 GAAP EPS $(0.44), Inline
Benzinga Newsdesk
Thursday, July 25, 2024
BioAtla Provides Clinical Program And Pipelin...
Benzinga Newsdesk
Tuesday, July 23, 2024
BioAtla Granted FDA Fast Track Designation Fo...
Benzinga Newsdesk
Thursday, May 23, 2024
JMP Securities Maintains Market Outperform on...
Benzinga Newsdesk
Wednesday, May 15, 2024
BioAtla shares are trading higher after the c...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on BioAtla...
Benzinga Newsdesk
Tuesday, May 14, 2024
BioAtla shares are trading higher after the c...
Benzinga Newsdesk
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
BioAtla Q1 2024 GAAP EPS $(0.48) Beats $(0.54...
Benzinga Newsdesk
Monday, May 06, 2024
BioAtla Announces FDA Clearance Of Investigat...
Benzinga Newsdesk
Thursday, May 02, 2024
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
Thursday, March 28, 2024
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
Wednesday, March 27, 2024
BioAtla shares are trading higher after the c...
Benzinga Newsdesk
HC Wainwright & Co. Maintains Buy on BioAtla,...
Benzinga Newsdesk
Tuesday, March 26, 2024
BioAtla Q4 EPS $(0.56) Beats $(0.79) Estimate
Benzinga Newsdesk
BioAtla: Q4 Earnings Insights
Benzinga Insights
Earnings Scheduled For March 26, 2024
Benzinga Insights
Monday, March 25, 2024
Preview: BioAtla's Earnings
Benzinga Insights
Wednesday, December 20, 2023
Around $2M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Avi Kapoor
Monday, December 18, 2023
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
Wednesday, December 13, 2023
BioAtla Hosting Virtual R&D Day To Highlight ...
Benzinga Newsdesk
Tuesday, December 05, 2023
JMP Securities Reiterates Market Outperform o...
Benzinga Newsdesk
BioAtla Presented Phase 2 Clinical Trial Data...
Benzinga Newsdesk
Monday, December 04, 2023
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
Wednesday, November 08, 2023
HC Wainwright & Co. Maintains Buy on BioAtla,...
Benzinga Newsdesk
Tuesday, November 07, 2023
BioAtla Q3 2023 Cash, Cash Equivalents $141.3...
Benzinga Newsdesk
BioAtla Sees H2 2025 Cash Balance $141.3M
Benzinga Newsdesk
Earnings Scheduled For November 7, 2023
Benzinga Insights
Tuesday, October 10, 2023
BioAtla Provides Guidance on Near-Term Milest...
Benzinga Newsdesk
Monday, October 02, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
Monday, September 25, 2023
Analyst Ratings for BioAtla
Benzinga Insights
JP Morgan Maintains Overweight on BioAtla, Lo...
Benzinga Newsdesk
Friday, September 15, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
Wednesday, August 02, 2023
JP Morgan Maintains Overweight on BioAtla, Lo...
Benzinga Newsdesk
Show More
